Skip to main content
Fig. 4 | Molecular Cancer

Fig. 4

From: Bone morphogenetic protein 7 sensitizes O6-methylguanine methyltransferase expressing-glioblastoma stem cells to clinically relevant dose of temozolomide

Fig. 4

Sensitization of MGMT-expressing GSC to low-dose TMZ treatment by recombinant BMP7. a. The mRNA expression of bone morphogenetic protein receptor, type II (serine/threonine kinase) (BMPRII) in GSC was verified by sqRT-PCR analysis (a) and BMP7-induced Smad1/5/8 phosphorylation in GSC was assayed by Western blot analysis (b). b. GSC-parental and GSC-500 μM TMZ were treated with 35 μM TMZ, BMP7 (100 ng/ml) or combination of BMP and TMZ. Treatment procedures were described in the text. Representative photos were taken 6–8 days after treatment. c. The growth effects (a), cell apoptosis (b), and cell senescence (c) induced by the indicated treatments on GSC were determined by a cell proliferation assay, the measurement of Caspase3/7 activity, and senescence-associated beta-galactosidase staining respectively. Blue staining in cells is indicative of cellular senescence (c). Data in (a) and (b) represent mean values ± SD of triplicate measurements in three independent experiments. *p < 0.05 and **p < 0.001 in relation to untreated GSC

Back to article page

Molecular Cancer

ISSN: 1476-4598